Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine

Por Ceccon, Garry, Wollring, Michael, Brunn, Anna, Deckert, Martina, Waldschmidt, Dirk, Fink, Gereon R., Galldiks, Norbert
Publicado no Case Rep Oncol (2020)

Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target

Por Loeser, Heike, Waldschmidt, Dirk, Kuetting, Fabian, Heydt, Carina, Zander, Thomas, Plum, Patrick, Alakus, Hakan, Buettner, Reinhard, Quaas, Alexander
Publicado no Mol Clin Oncol (2017)

Proposal for a definition of "Oligometastatic disease in pancreatic cancer"

Por Damanakis, Alexander I., Ostertag, Luisa, Waldschmidt, Dirk, Kütting, Fabian, Quaas, Alexander, Plum, Patrick, Bruns, Christiane J., Gebauer, Florian, Popp, Felix
Publicado no BMC Cancer (2019)

Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib – results from a non-interventional multi-center study

Por Westphalen, C. Benedikt, Kukiolka, Tobias, Garlipp, Benjamin, Hahn, Lars, Fuchs, Martin, Malfertheiner, Peter, Reiser, Marcel, Kütting, Fabian, Heinemann, Volker, Beringer, Andreas, Waldschmidt, Dirk T.
Publicado no BMC Cancer (2020)

Somatic BRCA1-associated protein 1 (BAP1) loss is an early and rare event in esophageal adenocarcinoma

Por Loeser, Heike, Waldschmidt, Dirk, Kuetting, Fabian, Schallenberg, Simon, Zander, Thomas, Bollschweiler, Elfriede, Hoelscher, Arnulf, Weckermann, Katharina, Plum, Patrick, Alakus, Hakan, Buettner, Reinhard, Quaas, Alexander
Publicado no Mol Clin Oncol (2017)

Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma

Por Quaas, Alexander, Heydt, Carina, Waldschmidt, Dirk, Alakus, Hakan, Zander, Thomas, Goeser, Tobias, Kasper, Philipp, Bruns, Christiane, Brunn, Anna, Roth, Wilfried, Hartmann, Nils, Bunck, Anne, Schmidt, Matthias, Buettner, Reinhard, Merkelbach-Bruse, Sabine
Publicado no BMC Gastroenterol (2019)

AB051. P-19. A phase II study of infigratinib (BGJ398) in previously-treated advanced cholangiocarcinoma containing FGFR2 fusions

Por Javle, Milind, Kelley, R. Kate, Roychowdhury, Sameek, Weiss, Karl Heinz, Abou-Alfa, Ghassan K., Macarulla, Teresa, Sadeghi, Saeed, Waldschmidt, Dirk, Zhu, Andrew X., Goyal, Lipika, Borad, Mitesh, Yong, Wei Peng, Borbath, Ivan, El-Khoueiry, Anthony, Philip, Philip, Moran, Susan, Ye, Yining, Ising, Mary, Lewis, Nancy, Bekaii-Saab, Tanios
Publicado no Hepatobiliary Surg Nutr (2019)

Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3...

Por Heinemann, Volker, Vehling-Kaiser, Ursula, Waldschmidt, Dirk, Kettner, Erika, Märten, Angela, Winkelmann, Cornelia, Klein, Stefan, Kojouharoff, Georgi, Gauler, Thomas C, von Weikersthal, Ludwig Fischer, Clemens, Michael R, Geissler, Michael, Greten, Tim F, Hegewisch-Becker, Susanna, Rubanov, Oleg, Baake, Gerold, Höhler, Thomas, Ko, Yon D, Jung, Andreas, Neugebauer, Sascha, Boeck, Stefan
Publicado no Gut (2012)